STOCK TITAN
  1. Home
  2. News
  3. ONTX

Traws Pharma, Inc. - ONTX STOCK NEWS

Welcome to our dedicated page for Traws Pharma news (Ticker: ONTX), a resource for investors and traders seeking the latest updates and insights on Traws Pharma stock.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule drug candidates aimed at treating cancer. Utilizing a proprietary chemistry platform, Onconova has developed an extensive library of targeted anti-cancer agents designed to interfere with specific cellular pathways critical to cancer cells while minimizing harm to normal cells.

The company's core business is centered on three key product candidates currently in clinical trials and six active pre-clinical programs. These innovative treatments aim to improve patient outcomes by directly addressing the disease, reducing recurrence, and lessening the side effects commonly associated with existing therapies.

Among its recent achievements, Onconova has made significant strides in translational science to better understand the pathways affected by its lead drug candidate, rigosertib. This research is expected to guide future clinical studies and combination treatments for challenging cancer types.

Onconova regularly hosts conference calls and webcasts to update stakeholders on its progress. For instance, the company is scheduled to hold a conference call and webcast on November 14, 2023, to provide further insights into its ongoing projects and recent developments.

News

Traws Pharma Announces New Employee Inducement Grants

Rhea-AI Summary
Traws Pharma, Inc. announced equity awards to new employees post the acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. The awards include restricted stock equity grants to key individuals, with specific vesting conditions over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
management
-
News

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Rhea-AI Summary
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. have merged to form Traws Pharma, Inc., focusing on developing antivirals for influenza, COVID-19, and other infectious diseases. The merger will result in the new ticker symbol 'TRAW' on NASDAQ. The companies plan to raise $14 million through a private placement, expecting a cash balance of $28 million. Traws Pharma will advance the development of viroksavir, travaltrevir, and narazaciclib, with multiple catalysts expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
News

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced the presentation of preclinical studies at AACR 2024, focusing on characterizing rigosertib's mechanisms impacting cancer pathways. The studies highlighted rigosertib's impact on RAS-MAPK signaling, ROS-related proteins, and inflammation-related targets, potentially aiding in developing treatment regimens for challenging cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
News

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced preclinical data demonstrating narazaciclib's potential to inhibit tumor growth in ibrutinib-sensitive and -resistant settings, along with its ability to promote G1 cell cycle blockade and metabolic reprogramming. The company is planning dose escalation studies in lead indication LGEEC with a planned update in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.13%
Tags
none
-
News

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) announced preclinical data highlighting narazaciclib’s multi-kinase profile, broad anti-tumor activity, and increased anti-tumor immunity, compared to palbociclib and other CDK4/6 inhibitors. The data supports the potential use of narazaciclib in breast and ovarian cancers, with plans for registrational studies and update in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.4%
Tags
none
-
News

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

Rhea-AI Summary
Onconova Therapeutics, Inc. (ONTX) to Present at Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
conferences acquisition
News

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) reports progress on the registrational preparations for the narazaciclib program, highlighting target engagement and an acceptable safety profile. The company also confirms plans for the rigosertib trial and financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings
-
News

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Rhea-AI Summary
Onconova Therapeutics, Inc. (NASDAQ: ONTX) to host conference call and webcast on November 14, 2023 to discuss third quarter 2023 financial results and pipeline programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
earnings
-
News

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Rhea-AI Summary
Onconova Therapeutics announced that preclinical data shows narazaciclib's effectiveness in controlling tumor growth in mantle cell lymphoma, including resistant cases. The combination of narazaciclib and ibrutinib also demonstrated anti-tumor activity. The studies support the potential use of narazaciclib in MCL and other cyclin-dependent indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
News

Onconova Expands Leadership Team with Two Key Appointments

Rhea-AI Summary
Onconova Therapeutics has named Dr. Victor Moyo as Chief Medical Officer and Meena Arora as Vice President of Global Medical Affairs and R&D. Both appointments are expected to contribute to the success of the company's oncology programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
management

FAQ

What is the market cap of Traws Pharma (ONTX)?

The market cap of Traws Pharma (ONTX) is approximately 20.9M.

What does Onconova Therapeutics, Inc. specialize in?

Onconova Therapeutics specializes in developing novel small molecule drug candidates to treat cancer using its proprietary chemistry platform.

What are the key product candidates of Onconova Therapeutics?

Onconova has three key product candidates in clinical trials and six active pre-clinical programs aimed at treating cancer.

What recent achievements has Onconova made?

Onconova has advanced its understanding of cancer pathways affected by its lead drug candidate, rigosertib, guiding future clinical studies and combination treatments.

When is the next conference call scheduled?

Onconova’s next conference call and webcast are scheduled for November 14, 2023, at 4:30 p.m. ET.

How does Onconova's proprietary chemistry platform benefit cancer treatment?

The platform allows Onconova to create targeted anti-cancer agents that disrupt critical cellular pathways in cancer cells while causing minimal damage to normal cells.

What is Onconova's approach to improving cancer treatment outcomes?

Onconova aims to directly address cancer, reduce recurrence, and lessen the burden of treatment side effects through its novel drug candidates.

How does Onconova keep stakeholders informed about its progress?

Onconova hosts regular conference calls and webcasts to provide updates on its clinical trials, research, and overall progress.

What is the significance of rigosertib in Onconova's research?

Rigosertib is a key drug candidate in Onconova's pipeline, with ongoing translational science research aimed at optimizing its clinical use and combination treatment regimens.

How can interested parties participate in Onconova's conference calls?

Interested parties can join Onconova's conference calls by dialing the provided numbers, as announced in their scheduled updates.

What is the trading symbol for Onconova Therapeutics, Inc.?

Onconova Therapeutics, Inc. trades under the symbol ONTX on NASDAQ.

Stock ONTX logo
Traws Pharma, Inc.

Nasdaq:ONTX

ONTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ONTX Stock Data

20.90M
20.84M
0.78%
7.95%
0.1%
Biotechnology
Healthcare
Link
United States
Newtown